Evidence map›Paper›PMID 38956505›Full record

ArticleBMC neurology2024

Predictors of outcome in large vessel occlusion stroke patients with intravenous tirofiban treatment: a post hoc analysis of the RESCUE BT clinical trial.

Xiang Liu, Wencheng He, Meiqiong Li, Jie Yang, Jiacheng Huang, Weilin Kong, Changwei Guo, Jinrong Hu, Shuai Liu, Dahong Yang and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiang Liu *Department of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.ORCID http://orcid.org/0000-0002-9318-5838
Wencheng He *Department of Neurology, Guangxi Guiping People's Hospital, Guiping, Guangxi, China.
Meiqiong Li *Department of Neurology, Guangxi Guiping People's Hospital, Guiping, Guangxi, China.
Jie YangDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Jiacheng HuangDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Weilin KongDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Changwei GuoDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Jinrong HuDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Shuai LiuDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Dahong YangDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Jiaxing SongDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Zhouzhou PengDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Linyu LiDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Yan TianDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Wenjie ZiDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China.
Chengsong YueDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China. yuechengsong1987@sina.com.
Fengli LiDepartment of Neurology, The Second Affiliated Hospital, Xinqiao Hospital, Army Medical University, Third Military Medical University, Chongqing, 400037, China. lifengli01@yeah.net.

Funding

Chongqing Xinqiao Hospital Young Doctor Talent Incubation Program 2022YQB011
6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate the factors influencing good outcomes in patients receiving only intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.

methodsPost hoc exploratory analysis using the RESCUE BT trial identified consecutive patients who received intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke in 55 comprehensive stroke centers from October 2018 to January 2022 in China.

resultsA total of 521 patients received intravenous tirofiban, 253 of whom achieved a good 90-day outcome (modified Rankin Scale [mRS] 0-2). Younger age (adjusted odds ratio [aOR]: 0.965, 95% confidence interval [CI]: 0.947-0.982; p < 0.001), lower serum glucose (aOR: 0.865, 95%CI: 0.807-0.928; p < 0.001), lower baseline National Institutes of Health Stroke Scale (NIHSS) score (aOR: 0.907, 95%CI: 0.869-0.947; p < 0.001), fewer total passes (aOR: 0.791, 95%CI: 0.665-0.939; p = 0.008), shorter punctures to recanalization time (aOR: 0.995, 95%CI:0.991-0.999; p = 0.017), and modified Thrombolysis in Cerebral Infarction (mTICI) score 2b to 3 (aOR: 8.330, 95%CI: 2.705-25.653; p < 0.001) were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.

conclusionYounger age, lower serum glucose level, lower baseline NIHSS score, fewer total passes, shorter punctures to recanalization time, and mTICI scores of 2b to 3 were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke. CHINESE CLINICAL TRIAL REGISTRY IDENTIFIER: ChiCTR-IOR-17014167.

Indexed as

ThrombectomyTirofibanAdministration, IntravenousAgedEndovascular ProceduresFemaleFibrinolytic AgentsHumansIschemic StrokeMaleMiddle AgedPlatelet Aggregation InhibitorsStrokeTreatment OutcomeFibrinolytic AgentsPlatelet Aggregation InhibitorsTirofibanAcute large vessel occlusion strokeEndovascular thrombectomyForecastingTirofiban

Identifiers

PMID38956505
PMCPMC11218210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.